Anti Obesity Drugs-EMEA Market Status and Trend Report 2013-2023
Report Summary
Anti Obesity Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti Obesity Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Anti Obesity Drugs 2013-2017, and development forecast 2018-2023
Main market players of Anti Obesity Drugs in EMEA, with company and product introduction, position in the Anti Obesity Drugs market
Market status and development trend of Anti Obesity Drugs by types and applications
Cost and profit status of Anti Obesity Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Anti Obesity Drugs market as:
EMEA Anti Obesity Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Anti Obesity Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Oral Medicine
Diet Patch
Diet Tea
EMEA Anti Obesity Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Men
Women
EMEA Anti Obesity Drugs Market: Players Segment Analysis (Company and Product introduction, Anti Obesity Drugs Sales Volume, Revenue, Price and Gross Margin):
Pfizer
Merck
Roche
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Novo Nordisk
Eisai
Norgine
Arena Pharmaceuticals
Orexigen Therapeutics
Vivus
Alizyme
Rhythm Pharmaceuticals
Shionogi
Zafgan
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Anti Obesity Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti Obesity Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Anti Obesity Drugs 2013-2017, and development forecast 2018-2023
Main market players of Anti Obesity Drugs in EMEA, with company and product introduction, position in the Anti Obesity Drugs market
Market status and development trend of Anti Obesity Drugs by types and applications
Cost and profit status of Anti Obesity Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Anti Obesity Drugs market as:
EMEA Anti Obesity Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Anti Obesity Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Oral Medicine
Diet Patch
Diet Tea
EMEA Anti Obesity Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Men
Women
EMEA Anti Obesity Drugs Market: Players Segment Analysis (Company and Product introduction, Anti Obesity Drugs Sales Volume, Revenue, Price and Gross Margin):
Pfizer
Merck
Roche
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Novo Nordisk
Eisai
Norgine
Arena Pharmaceuticals
Orexigen Therapeutics
Vivus
Alizyme
Rhythm Pharmaceuticals
Shionogi
Zafgan
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTI OBESITY DRUGS
1.1 Definition of Anti Obesity Drugs in This Report
1.2 Commercial Types of Anti Obesity Drugs
1.2.1 Oral Medicine
1.2.2 Diet Patch
1.2.3 Diet Tea
1.3 Downstream Application of Anti Obesity Drugs
1.3.1 Men
1.3.2 Women
1.4 Development History of Anti Obesity Drugs
1.5 Market Status and Trend of Anti Obesity Drugs 2013-2023
1.5.1 EMEA Anti Obesity Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti Obesity Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Anti Obesity Drugs in EMEA 2013-2017
2.2 Consumption Market of Anti Obesity Drugs in EMEA by Regions
2.2.1 Consumption Volume of Anti Obesity Drugs in EMEA by Regions
2.2.2 Revenue of Anti Obesity Drugs in EMEA by Regions
2.3 Market Analysis of Anti Obesity Drugs in EMEA by Regions
2.3.1 Market Analysis of Anti Obesity Drugs in Europe 2013-2017
2.3.2 Market Analysis of Anti Obesity Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Anti Obesity Drugs in Africa 2013-2017
2.4 Market Development Forecast of Anti Obesity Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Anti Obesity Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Anti Obesity Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Anti Obesity Drugs in EMEA by Types
3.1.2 Revenue of Anti Obesity Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Anti Obesity Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anti Obesity Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Anti Obesity Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Anti Obesity Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Anti Obesity Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Anti Obesity Drugs by Downstream Industry in Africa
4.3 Market Forecast of Anti Obesity Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI OBESITY DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Anti Obesity Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTI OBESITY DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Anti Obesity Drugs in EMEA by Major Players
6.2 Revenue of Anti Obesity Drugs in EMEA by Major Players
6.3 Basic Information of Anti Obesity Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Anti Obesity Drugs Major Players
6.3.2 Employees and Revenue Level of Anti Obesity Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTI OBESITY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Pfizer
7.1.1 Company profile
7.1.2 Representative Anti Obesity Drugs Product
7.1.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Merck
7.2.1 Company profile
7.2.2 Representative Anti Obesity Drugs Product
7.2.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Merck
7.3 Roche
7.3.1 Company profile
7.3.2 Representative Anti Obesity Drugs Product
7.3.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Roche
7.4 GlaxoSmithKline
7.4.1 Company profile
7.4.2 Representative Anti Obesity Drugs Product
7.4.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.5 AstraZeneca
7.5.1 Company profile
7.5.2 Representative Anti Obesity Drugs Product
7.5.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.6 Boehringer Ingelheim
7.6.1 Company profile
7.6.2 Representative Anti Obesity Drugs Product
7.6.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
7.7 Novo Nordisk
7.7.1 Company profile
7.7.2 Representative Anti Obesity Drugs Product
7.7.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.8 Eisai
7.8.1 Company profile
7.8.2 Representative Anti Obesity Drugs Product
7.8.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Eisai
7.9 Norgine
7.9.1 Company profile
7.9.2 Representative Anti Obesity Drugs Product
7.9.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Norgine
7.10 Arena Pharmaceuticals
7.10.1 Company profile
7.10.2 Representative Anti Obesity Drugs Product
7.10.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
7.11 Orexigen Therapeutics
7.11.1 Company profile
7.11.2 Representative Anti Obesity Drugs Product
7.11.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
7.12 Vivus
7.12.1 Company profile
7.12.2 Representative Anti Obesity Drugs Product
7.12.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Vivus
7.13 Alizyme
7.13.1 Company profile
7.13.2 Representative Anti Obesity Drugs Product
7.13.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Alizyme
7.14 Rhythm Pharmaceuticals
7.14.1 Company profile
7.14.2 Representative Anti Obesity Drugs Product
7.14.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Rhythm Pharmaceuticals
7.15 Shionogi
7.15.1 Company profile
7.15.2 Representative Anti Obesity Drugs Product
7.15.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Shionogi
7.16 Zafgan
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI OBESITY DRUGS
8.1 Industry Chain of Anti Obesity Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI OBESITY DRUGS
9.1 Cost Structure Analysis of Anti Obesity Drugs
9.2 Raw Materials Cost Analysis of Anti Obesity Drugs
9.3 Labor Cost Analysis of Anti Obesity Drugs
9.4 Manufacturing Expenses Analysis of Anti Obesity Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI OBESITY DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Anti Obesity Drugs in This Report
1.2 Commercial Types of Anti Obesity Drugs
1.2.1 Oral Medicine
1.2.2 Diet Patch
1.2.3 Diet Tea
1.3 Downstream Application of Anti Obesity Drugs
1.3.1 Men
1.3.2 Women
1.4 Development History of Anti Obesity Drugs
1.5 Market Status and Trend of Anti Obesity Drugs 2013-2023
1.5.1 EMEA Anti Obesity Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti Obesity Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Anti Obesity Drugs in EMEA 2013-2017
2.2 Consumption Market of Anti Obesity Drugs in EMEA by Regions
2.2.1 Consumption Volume of Anti Obesity Drugs in EMEA by Regions
2.2.2 Revenue of Anti Obesity Drugs in EMEA by Regions
2.3 Market Analysis of Anti Obesity Drugs in EMEA by Regions
2.3.1 Market Analysis of Anti Obesity Drugs in Europe 2013-2017
2.3.2 Market Analysis of Anti Obesity Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Anti Obesity Drugs in Africa 2013-2017
2.4 Market Development Forecast of Anti Obesity Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Anti Obesity Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Anti Obesity Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Anti Obesity Drugs in EMEA by Types
3.1.2 Revenue of Anti Obesity Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Anti Obesity Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anti Obesity Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Anti Obesity Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Anti Obesity Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Anti Obesity Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Anti Obesity Drugs by Downstream Industry in Africa
4.3 Market Forecast of Anti Obesity Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI OBESITY DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Anti Obesity Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTI OBESITY DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Anti Obesity Drugs in EMEA by Major Players
6.2 Revenue of Anti Obesity Drugs in EMEA by Major Players
6.3 Basic Information of Anti Obesity Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Anti Obesity Drugs Major Players
6.3.2 Employees and Revenue Level of Anti Obesity Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTI OBESITY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Pfizer
7.1.1 Company profile
7.1.2 Representative Anti Obesity Drugs Product
7.1.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Merck
7.2.1 Company profile
7.2.2 Representative Anti Obesity Drugs Product
7.2.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Merck
7.3 Roche
7.3.1 Company profile
7.3.2 Representative Anti Obesity Drugs Product
7.3.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Roche
7.4 GlaxoSmithKline
7.4.1 Company profile
7.4.2 Representative Anti Obesity Drugs Product
7.4.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.5 AstraZeneca
7.5.1 Company profile
7.5.2 Representative Anti Obesity Drugs Product
7.5.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.6 Boehringer Ingelheim
7.6.1 Company profile
7.6.2 Representative Anti Obesity Drugs Product
7.6.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
7.7 Novo Nordisk
7.7.1 Company profile
7.7.2 Representative Anti Obesity Drugs Product
7.7.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.8 Eisai
7.8.1 Company profile
7.8.2 Representative Anti Obesity Drugs Product
7.8.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Eisai
7.9 Norgine
7.9.1 Company profile
7.9.2 Representative Anti Obesity Drugs Product
7.9.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Norgine
7.10 Arena Pharmaceuticals
7.10.1 Company profile
7.10.2 Representative Anti Obesity Drugs Product
7.10.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
7.11 Orexigen Therapeutics
7.11.1 Company profile
7.11.2 Representative Anti Obesity Drugs Product
7.11.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
7.12 Vivus
7.12.1 Company profile
7.12.2 Representative Anti Obesity Drugs Product
7.12.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Vivus
7.13 Alizyme
7.13.1 Company profile
7.13.2 Representative Anti Obesity Drugs Product
7.13.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Alizyme
7.14 Rhythm Pharmaceuticals
7.14.1 Company profile
7.14.2 Representative Anti Obesity Drugs Product
7.14.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Rhythm Pharmaceuticals
7.15 Shionogi
7.15.1 Company profile
7.15.2 Representative Anti Obesity Drugs Product
7.15.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Shionogi
7.16 Zafgan
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI OBESITY DRUGS
8.1 Industry Chain of Anti Obesity Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI OBESITY DRUGS
9.1 Cost Structure Analysis of Anti Obesity Drugs
9.2 Raw Materials Cost Analysis of Anti Obesity Drugs
9.3 Labor Cost Analysis of Anti Obesity Drugs
9.4 Manufacturing Expenses Analysis of Anti Obesity Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI OBESITY DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
